美罗华嵌合anti-CD20单克隆抗体治疗复发无痛性淋巴瘤:一半的病人回复four-dose治疗项目。
文章的细节
-
引用
复制到剪贴板 -
麦克劳克林P, Grillo-Lopez AJ,链接BK,利维R, Czuczman女士,威廉姆斯,海曼先生,Bence-Bruckler我,白色的CA, Cabanillas F, Jain V,何鸿燊广告,李斯特J, K韦,沈D, Dallaire BK
美罗华嵌合anti-CD20单克隆抗体治疗复发无痛性淋巴瘤:一半的病人回复four-dose治疗项目。
8月肿瘤防治杂志。1998;16(8):2825 - 33所示。
- PubMed ID
-
9704735 (在PubMed]
- 文摘
-
目的:CD20抗原表达于b细胞淋巴瘤的90%以上。它呼吁靶向治疗,因为它不脱落或调节。更有效地嵌合单克隆抗体介导宿主效应函数和免疫原性本身就是低于小鼠抗体。患者和方法:这是一个二审判的嵌合anti-CD20抗体,IDEC-C2B8。低品位复发或滤泡性淋巴瘤患者接受门诊治疗的IDEC-C2B8 375 mg / m2静脉注射每周4剂量。结果:从31个中心,166名患者。这个intent-to-treat组,48%回答道。中位随访时间为11.8个月,预计平均时间反应级数为13.0个月。血清抗体水平持续更长时间后第四注入比第一后,患者和高反应者和更低的肿瘤负荷。大多数的不良事件发生在第一次输液,1级或2; fever and chills were the most common events. Only 12% of patients had grade 3 and 3% grade 4 toxicities. A human antichimeric antibody was detected in only one patient. CONCLUSION: The response rate of 48% with IDEC-C2B8 is comparable to results with single-agent cytotoxic chemotherapy. Toxicity was mild. Attention needs to be paid to the rate of antibody infusion, with titration according to toxicity. Further investigation of this agent is warranted, including its use in conjunction with standard chemotherapy.